{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:06:02Z","timestamp":1790805962310,"version":"4.1.0"},"reference-count":124,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/14737140.2025.2482721","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T21:57:26Z","timestamp":1742594246000},"page":"517-528","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Imetelstat in myeloid malignancies: current data and future directions"],"prefix":"10.1080","volume":"25","author":[{"given":"Aram","family":"Bidikian","sequence":"first","affiliation":[{"name":"Yale School of Medicine and Yale New Haven Hospital","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[{"name":"Yale School of Medicine and Yale New Haven Hospital","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Kewan","sequence":"additional","affiliation":[{"name":"Yale School of Medicine and Yale New Haven Hospital","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"Yale School of Medicine and Yale New Haven Hospital","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Yale School of Medicine and Yale New Haven Hospital","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7605428"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01405-w"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00059-2"},{"issue":"2","key":"e_1_3_5_6_1","first-page":"433","article-title":"Telomerase activity in normal human epithelial cells","volume":"13","author":"Yasumoto S","year":"1996","unstructured":"Yasumoto S, Kunimura C, Kikuchi K, et al. Telomerase activity in normal human epithelial cells. Oncogene. 1996 Jul 18;13(2):433\u2013439.","journal-title":"Oncogene"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.06.007"},{"key":"e_1_3_5_8_1","unstructured":"U.S. Food & Drug Administration. FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-imetelstat-low-intermediate-1-risk-myelodysplastic-syndromes-transfusion-dependent"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01724-5"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503479"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02864"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6622"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.18.7049"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1346005"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2388"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.06.006"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12476"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/345458a0"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(92)90096-3"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03415-4"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.140239"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.13.6476"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6408(1996)18:2<173::AID-DVG10>3.0.CO;2-3"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.11.024"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01668"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4322"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.11.018"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16404"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1994-y"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081823"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663865"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0416"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11065-0"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-01222-8_16"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.200900187"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208760"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00653-5"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0918"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1117"},{"key":"e_1_3_5_41_1","unstructured":"DailyMed. Label: RYTELO- imetelstat sodium injection powder lyophilized for solution. National Library of Medicine; 2024 [cited 2024 Dec 26]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b0fab7ca-e578-43c5-9df6-bdaff4182257"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-01222-8_16"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.084103"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00430.x"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904794"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0009"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.044602"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2156793"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13619"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1094-7"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.01.006"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008360"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq552"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16884"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29913"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0118-9"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06070.x"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer.15.20"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2414071"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02031-7"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.08.001"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000016"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30903"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26771"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.10.8130"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000252"},{"issue":"14","key":"e_1_3_5_67_1","first-page":"3931","article-title":"A novel telomerase template antagonist (GRN163) as a potential anticancer agent","volume":"63","author":"Asai A","year":"2003","unstructured":"Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003 Jul 15;63(14):3931\u20133939.","journal-title":"Cancer Res"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2017.37.3.195"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.13"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01895"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199636"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203612"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908892"},{"key":"e_1_3_5_74_1","unstructured":"Geron. Geron announces European commission approval of RYTELO\u00ae (imetelstat) a first-in-class telomerase inhibitor for the treatment of adults with transfusion-dependent anemia due to lower-risk MDS. 2025 [cited 2025 Mar 13]. Available from: https:\/\/ir.geron.com\/investors\/press-releases\/press-release-details\/2025\/Geron-Announces-European-Commission-Approval-of-RYTELO-imetelstat-a-First-in-Class-Telomerase-Inhibitor-for-the-Treatment-of-Adults-With-Transfusion-Dependent-Anemia-Due-to-Lower-Risk-MDS\/default.aspx"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0046"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017423"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04002-9"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13700"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.181297"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30679"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.001"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009311"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022012"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1277453"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.78"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07584"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10924"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000564104.83392.dc"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.10.001"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13330"},{"key":"e_1_3_5_93_1","unstructured":"A randomized open-label phase 3 study to evaluate Imetelstat (GRN163L) versus Best Available Therapy (BAT) in patients with intermediate-2 or High-risk myelofibrosis (MF) Relapsed\/Refractory (R\/R) to Janus Kinase (JAK) inhibitor [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04576156"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199235"},{"key":"e_1_3_5_95_1","unstructured":"An open label phase 1\/1b study to evaluate the safety pharmacokinetics pharmacodynamics and clinical activity of imetelstat in combination with ruxolitinib in patients with myelofibrosis [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05371964"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203800"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443770"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442012"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-643346"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01020-4"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08467.x"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S79576"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03171-1"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012743"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659060"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2375"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.01.006"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3843.3843"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.252817"},{"issue":"4","key":"e_1_3_5_112_1","first-page":"619","article-title":"Clinical implications of telomerase activity levels in acute leukemia","volume":"3","author":"Ohyashiki JH","year":"1997","unstructured":"Ohyashiki JH, Ohyashiki K, Iwama H, et al. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res. 1997 Apr;3(4):619\u2013625.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00969.x"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11313"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.578.578"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-1101"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-2731"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194185"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207907"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0233"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9335"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2850"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0376-3"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14618"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu550"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200885"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2482721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:24:16Z","timestamp":1746185056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2482721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/14737140.2025.2482721"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2482721","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}